Use of Recombinant Factor VII in Cardiac Surgery
journal contributionposted on 2014-04-15, 00:00 authored by Mark Elizalde, Leonid Slobodskoy, Michael Diodato, James Chang, Edgar G. Chedrawy
The off-label use of recombinant human coagulation factor VIIa has been increasing to a number of different treatment areas since its original approval in 1999. Several US patents describe claims for FVIIa utilization in non-hemophilia patients, treatment of bleeding due to trauma, as a means to reverse major bleeding, including intracranial bleeding, induced from fibrinolytic therapy as well as a patent for using FVIIa in the treatment of bleeding for patients with bleeding disorders not caused by hemophilia, but rather bleeding disorders due to thrombocytopenia, platelet disorders, and von Willebrand’s disease. Bleeding after cardiac surgery remains a serious complication that can increase both morbidity and mortality. We review the off-label usage of recombinant factor VIIa as a hemostatic agent that may help control bleeding following cardiac surgery.
Publisher StatementThis is a copy of an article published in the Recent Patents on Cardiovascular Drug Discovery © 2012 Bentham Science Publishers available at benthamscience.com
PublisherBentham Science Publishers